Natixis Advisors’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$56.6M Sell
1,325,522
-542,522
-29% -$29.5M 0.06% 277
2026
Q1
$117M Sell
1,868,044
-340,596
-15% -$27.2M 0.16% 136
2025
Q4
$211M Sell
2,208,640
-298,125
-12% -$29.2M 0.3% 70
2025
Q3
$245M Buy
2,506,765
+1,904
+0.1% +$197K 0.36% 45
2025
Q2
$269M Buy
2,504,861
+338,446
+16% +$34.2M 0.43% 38
2025
Q1
$219M Buy
2,166,415
+136,346
+7% +$13.7M 0.4% 44
2024
Q4
$181M Buy
2,030,069
+184,264
+10% +$16.2M 0.34% 52
2024
Q3
$155M Buy
1,845,805
+96,451
+6% +$7.6M 0.3% 64
2024
Q2
$135M Buy
1,749,354
+64,068
+4% +$4.69M 0.29% 71
2024
Q1
$115M Sell
1,685,286
-32,901
-2% -$2.12M 0.27% 90
2023
Q4
$99.3M Sell
1,718,187
-57,240
-3% -$3.06M 0.26% 92
2023
Q3
$93.7M Buy
1,775,427
+902,424
+103% +$47.3M 0.29% 81
2023
Q2
$47.2M Sell
873,003
-159,008
-15% -$8.3M 0.15% 157
2023
Q1
$51.6M Sell
1,032,011
-1,771
-0.2% -$83.5K 0.18% 137
2022
Q4
$47.8M Buy
1,033,782
+180,729
+21% +$7.83M 0.18% 147
2022
Q3
$33M Buy
853,053
+269,361
+46% +$10.8M 0.14% 177
2022
Q2
$21.8M Sell
583,692
-60,738
-9% -$2.47M 0.1% 250
2022
Q1
$28.5M Buy
644,430
+49,523
+8% +$2.15M 0.11% 203
2021
Q4
$25.3M Buy
594,907
+13,272
+2% +$558K 0.1% 233
2021
Q3
$25.2M Sell
581,635
-21,833
-4% -$966K 0.1% 207
2021
Q2
$25.8M Buy
603,468
+24,588
+4% +$1.03M 0.12% 196
2021
Q1
$22.4M Buy
578,880
+44,594
+8% +$1.69M 0.12% 207
2020
Q4
$19.2M Buy
534,286
+48,028
+10% +$1.73M 0.11% 216
2020
Q3
$18.6M Buy
486,258
+25,099
+5% +$967K 0.12% 208
2020
Q2
$16.2M Buy
461,159
+76,047
+20% +$2.74M 0.11% 218
2020
Q1
$12.6M Buy
385,112
+187,067
+94% +$7.31M 0.1% 225
2019
Q4
$8.96M Buy
198,045
+17,365
+10% +$727K 0.06% 339
2019
Q3
$7.35M Buy
180,680
+38,832
+27% +$1.65M 0.06% 354
2019
Q2
$6.1M Buy
141,848
+11,530
+9% +$443K 0.05% 398
2019
Q1
$5M Sell
130,318
-6,697
-5% -$256K 0.04% 444
2018
Q4
$4.84M Buy
137,015
+2,613
+2% +$94.8K 0.05% 422
2018
Q3
$5.17M Sell
134,402
-8,651
-6% -$302K 0.05% 449
2018
Q2
$4.68M Sell
143,053
-2,355
-2% -$71K 0.04% 482
2018
Q1
$3.97M Buy
145,408
+27,422
+23% +$745K 0.04% 517
2017
Q4
$2.92M Buy
117,986
+71,031
+151% +$1.96M 0.03% 584
2017
Q3
$1.37M Sell
46,955
-2,885
-6% -$79.7K 0.01% 804
2017
Q2
$1.38M Buy
49,840
+5,513
+12% +$146K 0.02% 795
2017
Q1
$1.1M Sell
44,327
-3,729
-8% -$90.7K 0.01% 839
2016
Q4
$1.04M Sell
48,056
-11,297
-19% -$246K 0.01% 820
2016
Q3
$1.41M Buy
59,353
+1,839
+3% +$43.9K 0.02% 726
2016
Q2
$1.34M Buy
57,514
+11,136
+24% +$241K 0.02% 725
2016
Q1
$872K Buy
46,378
+3,022
+7% +$53.1K 0.01% 821
2015
Q4
$799K Sell
43,356
-6,347
-13% -$114K 0.01% 804
2015
Q3
$816K Buy
49,703
+11,007
+28% +$188K 0.01% 818
2015
Q2
$685K Buy
38,696
+7,774
+25% +$139K 0.01% 851
2015
Q1
$549K Sell
30,922
-2,619
-8% -$41.4K 0.01% 897
2014
Q4
$444K Buy
33,541
+835
+3% +$10.7K 0.01% 940
2014
Q3
$386K Buy
32,706
+5,857
+22% +$73.8K 0.01% 940
2014
Q2
$343K Buy
26,849
+34
+0.1% +$442 ﹤0.01% 1113
2014
Q1
$363K Sell
26,815
-7,994
-23% -$105K 0.01% 1024
2013
Q4
$418K Buy
34,809
+3,772
+12% +$44.6K 0.01% 934
2013
Q3
$364K Sell
31,037
-1,185
-4% -$12.8K 0.01% 925
2013
Q2
$299K Buy
+32,222
New +$273K 0.01% 932

Other funds holding BSX

Natixis Advisors's BSX Position: Q2 2026 in Review

Natixis Advisors reduced its Boston Scientific (BSX) stake by 29% in Q2 2026, selling an estimated $29.5M and leaving 1,325,522 shares worth $56.6M. The position accounts for 0.06% of the portfolio, ranked #277.

Natixis Advisors first reported a position in BSX in Q2 2013 and has held it in 53 quarters since. The position peaked at $269M in Q2 2025. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Natixis Advisors held 1,325,522 shares of Boston Scientific worth $56.6M as of Q2 2026.
  • Natixis Advisors sold 542,522 Boston Scientific shares in Q2 2026, an estimated $29.5M.
  • Boston Scientific made up 0.06% of Natixis Advisors's portfolio in Q2 2026, its #277 holding.
  • Natixis Advisors first reported a position in Boston Scientific in Q2 2013 and has held it in 53 quarters since.
  • Natixis Advisors's Boston Scientific position peaked at $269M in Q2 2025.
  • 1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.